Form 4 for BVS Bioventus Inc.
Accepted 2026-01-13 00:00:00 ET · period of report 2026-01-09 · accession 0002005474-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-13 | 2026-01-09 | BVS | Claypoole Robert E | Pres, CEO, Dir | F - Tax | $8.03 | -41.7K | 117.0K | -26% | -$335.0K |
| D | 2026-01-13 | 2026-01-09 | BVS | Claypoole Robert E | Pres, CEO, Dir | M - OptEx | $0.00 | +93.8K | 158.7K | +144% | $0 |
| D | 2026-01-13 | 2026-01-09 | BVS | Claypoole Robert E | Pres, CEO, Dir | M - OptEx | $0.00 | -93.8K | 187.5K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-01-09 | F | D | 41,717 | $8.03 | 116,997 | D | — | — | |
| 2 | Common | Class A Common Stock | 2026-01-09 | M | A | 93,750 | $0.00 | 158,714 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2026-01-09 | M | D | 93,750 | $0.00 | 187,500 | D | — · — to — | 93,750 Class A Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. (F2) The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |